Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway

被引:1
|
作者
Choi, Young-Jin [1 ,2 ,3 ]
Fan, Meiqi [4 ]
Wedamulla, Nishala Erandi [1 ,2 ,3 ,5 ]
Tang, Yujiao [6 ]
Kim, Eun-Kyung [1 ,7 ,8 ]
机构
[1] Dong A Univ, Dept Food Sci & Nutr, Busan 49315, South Korea
[2] Dong A Univ, Brain Busan Plus Program 21, Ctr Silver Targeted Biomat, Busan 49315, South Korea
[3] Dong A Univ, Grad Sch, Dept Hlth Sci, Busan 49315, South Korea
[4] Konkuk Univ, Coll Biomed & Hlth Sci, Div Food Biosci, Chungju 27478, South Korea
[5] Uva Wellassa Univ, Fac Anim Sci & Export Agr, Dept Export Agr, Badulla 90000, Sri Lanka
[6] Changchun Univ Sci & Technol, Sch Biosci & Food Engn, Changchun 130600, Peoples R China
[7] Dong A Univ, Grad Sch Educ, Nutr Educ Major, Busan 49315, South Korea
[8] Nutrin Lab Co Ltd, Busan 49315, South Korea
基金
新加坡国家研究基金会;
关键词
Isoquercetin; Benign prostatic hyperplasia; Androgen receptor signaling; PI3K/Akt/mtor pathway; QUERCETIN; AUTOPHAGY; RAPAMYCIN; INSULIN; MTOR; INHIBITION; ANTIOXIDANT; METABOLISM; APOPTOSIS; THERAPY;
D O I
10.26599/FSHW.2022.9250216
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
We evaluated the effect of isoquercetin (quercetin-O-3-glucoside-quercetin, IQ) as a functional component of Abeliophyllum disistichum Nakai ethanol extract (ADLE) on prostate cell proliferation and apoptosis and its effects on the IGF-1/PI3K/Akt/mTOR pathway in benign prostatic hyperplasia (BPH). Metabolites in ADLE were analyzed using UHPLC-qTOF-MS and HPLC. IQ was orally administered (1 or 10 mg/kg) to a testosterone propionate-induced BPH rat model, and its effects on the prostate weight were evaluated. The effect of IQ on androgen receptor (AR) signaling was analyzed in LNCaP cells. Whether IGF-1 and IQ affect the IGF-1/PI3K/Akt/mTOR pathway in BPH-1 cells was also examined. The metabolites in ADLE were identified and quantified, which confirmed that ADLE contained abundant IQ (20.88 mg/g). IQ significantly reduced the prostate size in a concentration-dependent manner in a BPH rat model, and significantly decreased the expression of AR signaling factors in the rat prostate tissue and LNCaP cells in a concentration-dependent manner. IQ also inhibited the PI3K/AKT/mTOR pathway activated by IGF-1 treatment in BPH-1 cells. In BPH-1 cells, IQ led to G0/G1 arrest and suppressed the expression of proliferation factors while inducing apoptosis. Thus, IQ shows potential for use as a pharmaceutical and nutraceutical for BPH. (c) 2024 Beijing Academy of Food Sciences. Publishing services by Tsinghua University Press. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
下载
收藏
页码:1698 / 1710
页数:13
相关论文
共 50 条
  • [21] IGF-1对Rh1肉瘤细胞PI3K/Akt/mTOR信号通路的影响
    金家红
    黄文峰
    中国老年学杂志, 2011, 31 (22) : 4384 - 4385
  • [22] Effect of glucocorticoids on SCN injury and the PI3K/AKT/mTOR signaling pathway
    Yao, Zhipeng
    Liu, Wenge
    Zhou, Linquan
    Song, Chenyang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (05): : 3679 - 3685
  • [23] Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway
    Zhang, X.
    Yang, K.
    Zhang, H.
    Dong, W.
    Peng, W.
    Zhao, Y.
    HERZ, 2020, 45 (SUPPL 1) : 113 - 122
  • [24] Nutrient weight against sarcopenia: regulation of the IGF-1/PI3K/Akt/FOXO pathway in quinoa metabolites
    Liu, Pei-jie
    Hu, Yu-shi
    Wang, Min-jia
    Kang, Liang
    CURRENT OPINION IN PHARMACOLOGY, 2021, 61 : 136 - 141
  • [25] Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization
    Sasore, Temitope
    Reynolds, Alison L.
    Kennedy, Breandan N.
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 805 - 811
  • [26] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [27] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [28] Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis
    Mammana, Santa
    Fagone, Paolo
    Cavalli, Eugenio
    Basile, Maria Sofia
    Petralia, Maria Cristina
    Nicoletti, Ferdinando
    Mangano, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S51 - S51
  • [29] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [30] The pathway of PI3K/AKT/mTOR in pulmonary carcinoids.
    Zhang, Zixuan
    Wang, Mengzhao
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)